106274-68-4Relevant articles and documents
A comparative study of the recent most potent small-molecule PD-L1 inhibitors: what can we learn?
Liu, Mei,Zhang, Yu,Guo, Yu,Gao, Jian,Huang, Wenhai,Dong, Xiaowu
, p. 1230 - 1239 (2021)
Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have become a “game-changer” in the cancer treatment. However, none of the small molecular inhibitors has been approved yet. To explore the advantages and disadvantages of various scaffolds, di
TBPB-initiated cascade cyclization of 3-arylethynyl-[1,1′-biphenyl]-2-carbonitriles with sulfinic acids: Access to sulfone-containing cyclopenta[: Gh] phenanthridines
Wu, Meixia,Zhang, Man,Zhou, Nengneng,Zhou, Wei,Zhou, Xiaoqiang
, p. 1733 - 1737 (2020)
A novel TBPB-initiated cascade cyclization of 3-arylethynyl-[1,1′-biphenyl]-2-carbonitriles with sulfinic acids via C-S, C-C and C-N bond formation for the synthesis of 3-sulfonated cyclopenta[gh]phenanthridines under metal-free conditions has been developed. This protocol features mild conditions, good functional group tolerance and a broad substrate scope. By using this protocol, a variety of potentially bioactive 3-sulfonated cyclopenta[gh]phenanthridines were facilely synthesized via direct annulation.
HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
-
, (2017/07/14)
Disclosed are compounds of Formula (I′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.